Key Drivers
- No Revenue
- Cash Burn
- Dilution Risk
AIAI Summary
SYRE should be viewed as a catalyst-driven clinical biotech with a fortress balance sheet—not a valuation story yet—because $741M in cash and runway into 2H 2029 sharply reduce financing risk, but the stock still ultimately hinges on whether early SPY001/SPY002 signals convert into durable, placebo-controlled proof amid ongoing dilution and binary trial risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •No Revenue
- •Cash Burn
- •Dilution Risk
SYRE has a debt-free, cash-rich balance sheet, but zero revenue, ongoing losses, negative free cash flow, and dilution make the stock look expensive and high risk.
Price Behavior
Key Price Behavior Insights:
- •Higher-lows pattern
- •Momentum cooled
- •Reclaim $90
SYRE remains in an uptrend over the last month, but the late-June reversal from $100.32 and failure to hold $90 signal fading momentum, with $86-$87 support and $90-$100 resistance now in focus.
Sharp reversal from $100.32 on 2026-06-22 to $86.24 on 2026-06-24
Sentiment & News
Key News Insights:
- •UC readout
- •Cash runway
- •2026 catalysts
Spyre Therapeutics showed encouraging early ulcerative colitis data and a strong cash runway, but the stock's next move now hinges on upcoming 2026 clinical catalysts.
The news is moderately bullish, as early clinical momentum and financial flexibility support the stock while investors wait for confirmatory trial results
Similar Companies in Healthcare
Other companies in the same sector with AI ratings